PCM
APLS

Palisade Capital Management’s Apellis Pharmaceuticals APLS Stock Holding History

Palisade Capital Management’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-35,583
Closed -$1.17M – 427
2021
Q3 		$1.17M Buy
+35,583
New +$2M 0.03% 325

Other funds holding APLS

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Palisade Capital Management's APLS Position: Q4 2021 in Review

Palisade Capital Management sold out of Apellis Pharmaceuticals (APLS) in Q4 2021, closing a stake of 35,583 shares — an estimated $1.17M sold.

Palisade Capital Management first reported a position in APLS in Q3 2021 and held it in 1 quarter. The position peaked at $1.17M in Q3 2021. 186 funds tracked by Wall St. Rank hold APLS as of Q4 2021.

  • Palisade Capital Management reported no remaining Apellis Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
  • Palisade Capital Management sold 35,583 Apellis Pharmaceuticals shares in Q4 2021, an estimated $1.17M.
  • Palisade Capital Management first reported a position in Apellis Pharmaceuticals in Q3 2021 and held it in 1 quarter.
  • Palisade Capital Management's Apellis Pharmaceuticals position peaked at $1.17M in Q3 2021.
  • 186 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q4 2021.

Based on Palisade Capital Management's 13F filing for Q4 2021, filed 10 Feb 2022.